A saga of 2 companies with CEOs named Paul, and deals with PFE,
one is valued at 95 million, and up 140 % ytd, the other is valued at 475 million, and down 1 % ytd. Bothhave had earnings and cc in the past week. Both have been rumored to be possible take overtargets by PFE. Wil be interesting to see if PFE buys one, both, or neither.
mbus, I honestly was surprised with you question, thought I had mentioned it. It is PSDV, they are in eye treatment, mainly the back of the eye. They have some good things cooking, a drug, iluvian, already on the market in Eurpe, awaiting fda final approval here, after prvious rejection. they have modified the submission thistime, should be approved. They has earnings and cc today, though earings is not their primary value at this time. People must have liked it, up over a dime after hours.Check it out, nothing to lose. By the way, also heck out NSPH. gl